Breast Cancer Research and Treatment

, Volume 100, Issue 1, pp 59–63

Premature Menopause in Patients with BRCA1 Gene Mutation

  • Izabella Rzepka-Górska
  • Bogusław Tarnowski
  • Anita Chudecka-Głaz
  • Bohdan Górski
  • Dorota Zielińska
  • Aleksandra Tołoczko-Grabarek
Clinical Trial

Abstract

This study was undertaken with regard to the gonadotropin theory of ovarian cancer advocated in the literature and was designed to disclose specific features of ovarian morphology in carriers of the BRCA1 gene mutation. We enrolled 171 patients and divided them into two groups: A (n=90)—operated for breast cancer (30 patients with and 60 without the BRCA1 mutation); B (n=81)—with the BRCA1 mutation qualified for preventive adnexectomy. According to the authors’ classification described herein, some patients without the BRCA1 mutation retained “signs of estrogenization” in menopausal ovaries, revealing the role of estrogens as a factor promoting mammary carcinogenesis in these patients. A tendency to premature menopause was observed in BRCA1 mutation carriers of groups A and B as evidenced by the final menorrhea appearing at a younger age and almost total absence of “signs of estrogenization” in menopausal ovaries. It is concluded from these findings that earlier menopause in carriers of the BRCA1 mutation is associated with hypergonadotropic activity and may predispose to ovarian cancer at younger age.

Keywords

BRCA 1 gene mutation Premature menopause Breast cancer Genetics Oncology 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Górski B, Byrski T, Huzarski T, Jakubowska A, Menkiszak J, Gronwald J, Płużańska A, Bębenek M, Fischer-Maliszewska L, Grzybowska E, Narod SA, Lubiński J (2000) Founder mutations in BRCA1 gene in Polish families with breast ovarian cancer. Am J Hum Genet 66:1963–1968PubMedCrossRefGoogle Scholar
  2. 2.
    Górski B, Jakubowska A, Huzarski T, Byrski T, Gronwald J, Grzybowska E, Mackiewicz A, Stawicka M, Bębenek M, Sorokin D, Fischer-Maliszewska L, Haus O, Janiszewska H, Niepsuj S, Głódź S, Zaremba L, Posmyk M, Płużańska M, Kilar E, Czudowska D, Waśko B, Miturski R, Kowalczyk JR, Urbański K, Szwiec M, Koc J, Dębniak B, Rozmiarek A, Dębniak T, Cybulski C, Kowalska E, Tołoczko-Grabarek A, Zajączek S, Menkiszak J, Mędrek K, Masojć B, Mierzejewski M, Narod SA, Lubiński J (2004) A high proportion of founder BRCA1 mutations in Polish breast cancer families. Int J Cancer 110:683–696PubMedCrossRefGoogle Scholar
  3. 3.
    Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubiński J, Gronwald J. Górski B, Tulinius H, Thorlacius S, Eerola H, Nevanlinna H, Syrjakoski K, Kallioniemi OP, Thompson D, Evans C, Peto J, Lalloo F, Evans DG, Easton DF (2003) Average risk of breast and ovarian cancer associated with BRCA1 or BRCA2 mutation detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72:1117–1130PubMedCrossRefGoogle Scholar
  4. 4.
    Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE (1994) Risk of cancer in BRCA1-mutation carriers. Breast cancer linkage consortium. Lancet 343:692–695PubMedCrossRefGoogle Scholar
  5. 5.
    Elit L, Rosen B, Goel V, McLaughlin J, Fung MK, Shime J, Narod S (2001) Prophylactic oophorectomy in Ontario. Fam Cancer 1:143–148PubMedCrossRefGoogle Scholar
  6. 6.
    Olopade OI, Artioli G (2004) Efficacy of risk-reducing salpingo-oophorectomy in women with BRCA-1 and BRCA-2 mutations. Breast J 10 (Suppl. 1): 5–9CrossRefGoogle Scholar
  7. 7.
    Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, Van’t Veer L, Garber JE, Evans G, Isaacs C, Daly MB, Matloff E, Olopade OI, Weber BL (2002) Prevention and observation of surgical end points study group: prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. New Eng J Med 346:1616–1622PubMedCrossRefGoogle Scholar
  8. 8.
    Rebbeck TR, Levin AM, Eisen A, Snyder C, Watson P, Cannon-Albr L, Isaacs C, Olopade O, Garber JE, Godwin AK, Daly MB, Narod SA, Neuhausen SL, Lynch HT, Weber BL (1999) Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst 9:1475–1479CrossRefGoogle Scholar
  9. 9.
    Rebbeck TR, Friebel T, Wagner T, Lynch HT, Garber JE, Daly MB, Isaacs C, Olopade OI, Neuhausen SL, van‘t Veer L, Eeles R, Evans DG, Tomlinson G, Matloff E, Narod SA, Eisen A, Domchek S, Armstrong K, Weber BL (2005) PROSE Study Group. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 23:7804–7810PubMedCrossRefGoogle Scholar
  10. 10.
    Menkiszak J, Rzepka-Górska I, Górski B, Gronwald J, Byrski T, Huzarski T, Jakubowska A, Metcalfe KA, Narod SA, Lubiński J (2004) Attitudes toward preventive oophorectomy among BRCA1 mutation carriers in Poland. Eur J Gynecol Oncol 25:93–95Google Scholar
  11. 11.
    Choi JH, Choi KC, Auersperg N, Leung PC (2005) Gonadotropins upregulate the epidermal growth factor receptor through activation of mitogen-activated protein kinases and phosphadil-inositol-3-kinase in human ovarian surface epithelial cells. Endocr Relat Cancer 12:407–421PubMedCrossRefGoogle Scholar
  12. 12.
    Schiffenbauer YS, Meir G, Maoz M, Evan-Ram SC, Bar-Shavit R, Neeman M (2002) Gonadotropin stimulation of MLS human epithelial ovarian carcinoma cells augments cell adhesion mediated by CD44 and by alpha(v)-integrin. Gynecol Oncol 84:296–302PubMedCrossRefGoogle Scholar
  13. 13.
    Parrot JA, Doraiswamy V, Km G etal. (2001) Expression and actions of both the follicle stimulating hormone receptor and the luteinizing hormone receptor in norma ovarian surface epithelium and ovarian cancer. Moll Cell Endocrinol 172:213–222CrossRefGoogle Scholar
  14. 14.
    Bose CK (2005) Role of nerve growth factor and FSH receptor in epithelial ovarian cancer. Reprod Biomed Online 11:194–197PubMedCrossRefGoogle Scholar
  15. 15.
    Mandai M, Konoshi I, Kuroda H etal. (1997) Messenger ribonucleic acid expression of Lh/hCG receptor gene in human ovarian carcinomas. Eur J Cancer 33:1501–1507PubMedCrossRefGoogle Scholar
  16. 16.
    Choi JH, Choi KC, Auersperg N, Leung PC (2004) Overexpression of follicle-stimulating hormone receptor activates oncogenic pathways in preneoplastic ovarian surface epithelial cells. J Clin Endocrinol Metab 89:5508–5518PubMedCrossRefGoogle Scholar
  17. 17.
    Johnstrom H, Borg K, Olsson H (2005) High follicular phase luteinizing levels in young healthy BRCA 1 mutation carriers: implication for breast and ovarian cancer risk. Mol Genet Metab 86:320–327CrossRefGoogle Scholar
  18. 18.
    Yue W, Santen RJ, Wang JP, Li Y, Verderame MF, Bocchinfuso WP, Korach KS, Devanesan P, Todorovic R, Rogan EG, Cavalieri EL (2003) Genotoxic metabolites of estradiol in breast: potential mechanism of estradiol induced carcinogenesis. J Steroid Biochem Mol Biol 86:477–486PubMedCrossRefGoogle Scholar
  19. 19.
    Evansa MD, Dizdaroglu M, Cooke MS (2004) Oxidative DNA damage and disease: induction, repair and significance. Mutat Res 567:1–61CrossRefGoogle Scholar
  20. 20.
    Hiraku Y, Yamashita N, Nishiguchi M, Kawanishi S (2001) Catechol estrogens induce oxidative DNA damage and estradiol enhances cell proliferation. Int J Cancer 92:333–337PubMedCrossRefGoogle Scholar
  21. 21.
    Casey MJ, Bewtra C, Hoehne LL, Tatpati AD, Lynch HT, Watson P (2000) Histology of prophylactically removed ovaries from BRCA 1 and BRCA 2 mutation carries compared with noncarriers in hereditary breast ovarian cancer syndrome kindred’s. Gynecol Oncol 78:278–287PubMedCrossRefGoogle Scholar
  22. 22.
    Barakat RR, Federici MG, Saigo PE, Robson ME, Offit K, Boyd J (2000) Absence of premalignant histologic, molecular, or cell biologic alternations in prophylactic oophorectomy specimens from BRCA 1 heterozygotes. Cancer 89:383–390PubMedCrossRefGoogle Scholar
  23. 23.
    Chudecka-Głaz A, Rzepka-Górska I, Kosmowska B (2004) Gonadotropin (LH, FSH) levels in serum and cyst fluid in epithelial tumors of the ovary. Arch Obstet Gynecol 270:151–156CrossRefGoogle Scholar
  24. 24.
    Rzepka-Górska I, Chudecka-Głaz A, Kosmowska B (2004) FSH and LH serum/tumor fluid ratios and malignant tumors of the ovary. Endocr Releat Cancer 11:315–321CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B. V. 2006

Authors and Affiliations

  • Izabella Rzepka-Górska
    • 1
  • Bogusław Tarnowski
    • 1
  • Anita Chudecka-Głaz
    • 1
  • Bohdan Górski
    • 2
  • Dorota Zielińska
    • 1
  • Aleksandra Tołoczko-Grabarek
    • 2
  1. 1.Department of Gynecological Surgery and Oncology of Adults and AdolescentsPomeranian Medical University of Szczecin, PolandSzczecinPoland
  2. 2.Department of Genetics and Pathology, Hereditary Cancer Center Pomeranian Medical University of Szczecin, PolandSzczecinPoland

Personalised recommendations